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Background: Intracranial hemorrhage (ICH) following carotid endarterectomy (CEA) or carotid artery stenting (CAS) is
a rare but potentially devastating complication. The effect of more intense dual antiplatelet therapy required for CAS on
the frequency of ICH has not been established. This study was undertaken to evaluate the nationwide occurrence of ICH
associated with CAS vs CEA.
Methods:TheNationwide Inpatient Sample was used to identify patients discharged after CAS and CEA during 2005. The
type of revascularization and major adverse events, ie, in-hospital ICH, postprocedural stroke, and death rates, were
determined by cross-tabulating specific procedural codes for CAS and CEA and diagnostic codes for carotid stenosis. Risk
stratification was performed using the Charlson Comorbidity Index. Univariate and multivariate logistic regression
analyses were used to assess the association between type of revascularization, comorbidities, ICH, and risk-adjusted
mortality.
Results: In 2005, the estimated number of carotid revascularizations was 135,903. The vast majority of patients
underwent CEA (90.4%), whereas CAS was performed in 13,093 (9.6%) patients. Most patients (92.2%) underwent
treatment for asymptomatic carotid stenosis. CAS patients had higher postoperative stroke rates (2.1% vs 1.1%; P< .001)
and in-hospital mortality (1.1% vs 0.6%; P < .001) than CEA patients. ICH occurred in 19 patients (0.15%) after CAS
and in 20 patients (0.016%) after CEA (P < .001). CAS was identified as an independent predictor for postoperative
stroke (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.5-2.0; P< .001), in-hospital mortality (OR, 1.49; 95%CI,
1.2-1.8; P < .001) and ICH (OR, 5.9; 95% CI, 3.1-11.1; P < .001) after adjusting for age, gender, symptomatic status,
comorbidities, admission, and hospital type using logistic regression. In-hospital mortality was 12.5% among patients
developing ICH (OR, 23.2; 95% CI, 9.1-54.4; P < .001).
Conclusion: In the United States, patients undergoing CAS have not only significantly increased postoperative stroke and
death rates compared with those undergoing CEA, but also a sixfold increased risk of ICH. Although ICH after CAS is
extremely rare, its devastating nature and high mortality warrant further investigation to define specific risk factors,
prevention, and treatment strategies. ( J Vasc Surg 2009;49:623-9.)Intracranial hemorrhage (ICH) after carotid endarter-
ectomy (CEA) occurs in 0.2% to 0.5% of cases and has
primarily been attributed to hyperperfusion syndrome
(HPS).1-4 ICH and HPS are probably related to the pre-
operative loss of vascular autoregulatory mechanisms in a
chronically hypoperfused cerebral hemisphere.5-7 HPS
usually manifests clinically as transient focal deficits associ-
ated with ipsilateral retro-orbital headache, seizures, and
only rarely ICH.5 Although hyperperfusion seems to occur
to some extent in most patients after carotid revasculariza-
tion, HPS develops only in 2% to 3% of patients undergoing
CEA.5 Both HPS and ICH are associated with significant
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doi:10.1016/j.jvs.2008.09.064morbidity and mortality, and they are well-described com-
plications of CEA.3,5,8
HPS and ICH have recently been described after ca-
rotid artery stenting (CAS).4,6,9,10 Although HPS has sim-
ilar manifestations after CAS as CEA, the overall outcomes
and prognosis appear to be worse after CAS.6,11 Further-
more, recent studies suggest a more acute onset and a
relatively higher incidence of ICH after CAS, which may be
greater than 5%.6,10,12 The potential effect of more intense
dual antiplatelet therapy required for CAS13 on the fre-
quency of ICH has not been established.
This study was undertaken to evaluate the nationwide
occurrence and outcomes of ICH associated with CAS vs
CEA in the United States. The objectives of this study were
to compare the frequency and risk factors for ICH occur-
ring during the same hospitalization after CAS as compared
with CEA. In addition, associations between type of carotid
revascularization (CAS vs CEA) and in-hospital ICH, post-
procedural stroke, and death were also assessed.
METHODS
The Nationwide Inpatient Sample (NIS) from the
Healthcare Cost and Utilization Project (HCUP) was used
to identify all CAS and CEA procedures performed in
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the United States.14 It represents a 20% stratified sample of
inpatient admissions to US academic, community, and
acute care hospitals nationwide (about 1000 hospitals in 38
states; excludes veterans affairs and other federal and prison
hospitals). Typical discharge data collected include demo-
graphics, primary and 14 different secondary diagnoses,
primary and 14 different secondary procedures per patient
as identified by the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) codes,
length of stay, charges, and outcomes. Sampling weights
are provided for accurate calculations based on the complex
survey design of the dataset. HCUP quality control proce-
dures are routinely performed to confirm that data values
are valid, consistent, and reliable.15 The NIS core inpatient
files were used for data extraction and analysis. Because NIS
data is publicly available and contains no personal identify-
ing information, this study was exempt from institutional
review board approval.
All CAS and CEA procedures performed in 2005 were
identified by linking the ICD-9-CM procedural codes for
CEA and CAS with a primary or secondary diagnosis of
carotid stenosis. The ICD-9-CM coding system has had a
specific code for CAS since 2004 (00.63). Thus, all CAS
procedures performed in 2005 can be accurately identified.
CEA procedures were also identified using a specific code
(38.12). Symptomatic status of patients with carotid steno-
sis was determined according to ICD-9-CM discharge di-
agnosis. Patients were classified as symptomatic if discharge
diagnosis was “carotid artery stenosis with stroke” or if
diagnosis codes included transient ischemic attacks (TIA)
or amaurosis fugax. Patients with discharge diagnosis of
“carotid artery stenosis without mention of stroke” with no
accompanying diagnoses for TIA or amaurosis fugax were
classified as asymptomatic. Based on 15 diagnosis codes
(ICD-9-CM) and the clinical classification software (CCS;
Agency for Healthcare Research and Quality, Rockville,
Md) coding system included in the data,16 comorbid med-
ical conditions were defined and used further to calculate a
comorbidity score based on themodified Charlson Comor-
bidity Index (CCI).17 The CCI is a validated measure for
use with administrative data that correlates with in-hospital
morbidity and mortality after surgical procedures, includ-
ing elective carotid interventions.18 Each of the indicated
diagnoses is assigned a weight and summed to provide a
patient’s total score. The CCI was further used to define
two surgical-risk-based groups according to comorbidities
(CCI1 indicating low-risk vs CCI1 indicating greatest
comorbidity) for analyses.
The primary outcome endpoint of this cross-sectional
population-based study was the occurrence of in-hospital
ICH and death after carotid revascularization procedures,
ie, ICH and/or deaths that occur after CEA or CAS during
the same hospitalization. All instances of ICH occurring in
patients undergoing CEA and CAS during the same hospi-
talization were identified using appropriate specific ICD-
9-CM codes (432, 432.0, 432.9, 430). In addition, the
occurrence of postoperative stroke was also assessed. Post-operative stroke was defined as an ICD-9-CM secondary
diagnostic code of “postoperative stroke (997.02)”. Post-
operative death was defined as any death occurring during
the same hospitalization. Mortality data was available di-
rectly from the dataset, which is entered as died during
hospitalization and is coded from disposition of patient.
Weighted analyses for predictors of in-hospital ICH,
stroke, and death included demographic data, symptomatic
status, preoperative comorbidities, and risk stratification,
which were based on the comorbidity index, and hospital
characteristics.
Descriptive statistics for categorical variables are pre-
sented as relative frequencies (percents), which were com-
pared with 2 test (2 for independent groups, two-tailed P
value). Continuous variables were expressed asmedians and
interquartile ranges and compared with nonparametric
tests. In-hospital ICH, stroke, and death rates were ad-
justed for patient age, gender, symptomatic status, andCCI
for risk-stratification using multivariate stepwise logistic
regression analyses. Findings were considered statistically
significant if the resulting P value was less than .05 for the
primary and secondary endpoints (in-hospital ICH, post-
operative stroke, and death). Multivariate odds ratios (OR)
are reported with 95% confidence intervals (CI). Nation-
wide estimates and weighted data analyses were obtained
using population-based procedures specific to the unique
NIS sample design. SAS version 9.1 (SAS Institute, Cary,
NC) was used for data analyses.
RESULTS
The estimated number of carotid revascularizations
performed nationwide in 2005 was 135,903. Most patients
underwent CEA (n  122,984; 90.4%), whereas CAS was
only performed in 13,093 (9.6%) patients. Of these, 76.5%
were elective carotid procedures. Patient characteristics and
comorbidities according to type of carotid revascularization
are listed in Table I. Most patients (92.2%) underwent
treatment for asymptomatic carotid stenosis. Among pa-
tients with symptomatic stenosis, 58% had TIA and 42%
had stroke listed as principal or secondary diagnoses.
Patients undergoing CAS had a significantly greater
prevalence of congestive heart failure and renal failure,
whereas patients undergoing CEA had a greater prevalence
of hypertension and chronic lung disease (Table I). Overall,
CAS patients had a higher surgical risk profile according to
the comorbidity index (32.8% with CCI 2 vs 29% in the
CEA group; P  .001). The percentage of octogenarians
was significantly higher in the CAS group compared with
the CEA group (21.2% vs 19.7%; P  .001). The median
length of stay among patients undergoing CAS (median, 1
day; interquartile range [IQR], 1-2 days) was significantly
shorter compared with patients undergoing CEA (median,
1 day; IQR, 1-3 days; P  .001). A higher proportion of
CAS procedures were classified as nonelective admissions
(34% vs 22.2%), and more were performed in teaching
hospitals (65.9% vs 40.4%) compared with CEA proce-
dures.
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19 patients (0.15%) undergoing CAS and in 20 patients
(0.016%) undergoing CEA (P  .001). In-hospital mor-
tality was 12.5% among patients developing ICH (OR,
23.2; 95% CI, 9.1-54.4; P  .001). Among patients that
developed ICH and underwent CAS, 5 of 19 (26%) died
during the same hospitalization, whereas no deaths oc-
curred among 20 patients that developed ICH and un-
derwent CEA.
Univariate analysis revealed that patients in the CAS
group had a 77% increased risk of postoperative stroke,
compared to patients undergoing CEA (OR, 1.77; 95% CI,
1.3-2.4; P  .001). Patients undergoing CAS also had
significantly higher postoperative stroke rates (2.1% vs
1.1%; P  .001) and in-hospital mortality (1.1% vs 0.6%;
P  .001) than CEA patients. Combined stroke and death
rates were also higher after CAS compared with CEA (2.8%
vs 1.5%; P  .001).
Stratified analyses according to symptomatic status and
type of carotid revascularization revealed that all 19 in-
stances of ICH after CAS occurred in asymptomatic pa-
tients. Alternatively, among patients undergoing CEA, 5
cases of ICH occurred in symptomatic patients and 15 in
asymptomatic patients. Symptomatic patients undergoing
CAS had higher postoperative stroke rates (5% vs 2.6%) and
in-hospital mortality (4.6% vs 1.4%) compared with pa-
tients undergoing CEA (P  .001). Similarly, asymptom-
atic patients in the CAS group had higher postoperative
stroke rates (1.8% vs 1%; P .001) and in-hospital mortal-
ity (0.7% vs 0.5%; P  .002) than those in the CEA group.
Multivariate logistic regression analysis revealed that
patients undergoing CAS had a sixfold increased risk of
ICH compared to those undergoing CEA after adjusting
Table I. Clinical characteristics of patients undergoing
CAS and CEA in 2005
CAS CEA
P value(n 13,093) (n 122,984)
Median age, year (IQR) 72 (64-78) 72 (65-78) .72*
Female gender, % 37.8 42.6  .001
†
Symptomatic carotid
stenosis, % 9.6 7.7 .24
Comorbidities, %
Hypertension 69.1 76.0  .001
†
Diabetes mellitus 28.4 29.3 .042
†
Chronic lung disease 17.6 21.2  .001
†
Previous myocardial
infarction 11.2 11.7 .117
Congestive heart failure 11.7 7.6  .001
†
Renal failure 5.0 3.5  .001
†
Charlson comorbidity
index, median (IQR) 1 (1-3) 1 (0-2)  .001*
Teaching hospital, % 65.9 40.4  .001
†
Elective admission, % 66.0 77.8  .001
†
CAS, Carotid artery stenting; CEA, carotid endarterectomy; IQR, inter-
quartile range.
*Mann-Whitney U test.
†2 analysis.for age, gender, symptomatic status, comorbidity index,admission, and hospital type (OR, 5.9; 95% CI, 3.1-11.1;
P  .001). Other independent predictors for ICH included
increasing patient age, female gender, comorbidity index,
renal failure, hypertension, and nonelective admission
(Table II). Multivariate logistic regression models also re-
vealed that CAS was associated with a 1.8-fold increased
risk of postoperative stroke compared with CEA after ad-
justing for age, gender, symptomatic status, comorbidities,
admission, and hospital type (OR, 1.77; 95% CI, 1.5-2.0;
P  .001).
ICH was identified as an independent predictor for
in-hospital mortality by multivariate regression analysis
(OR, 4.01; 95% CI, 1.5-10.9; P  .001). CAS was also
independently associated with a 1.5-fold increased risk of
in-hospital mortality compared with CEA (OR, 1.49; 95%
CI, 1.2-1.8; P  .001). Increasing patient age, female
gender, CCI, renal failure, symptomatic disease, and non-
elective admission were also identified as independent pre-
dictors of in-hospital mortality by stepwise logistic regres-
sion (Table II).
DISCUSSION
This nationwide population-based study indicates that
patients who undergo CAS have not only significantly
higher stroke and death rates compared with those under-
going CEA, but also significantly increased risk of ICH.
The US national statistics also specifically demonstrate that
CAS-related ICH is associated with significantly increased
risk of in-hospital mortality compared with ICH associated
with CEA. These results suggest that CEA is safer than CAS
in patients with increased risk of ICH. Further studies are
necessary to identify markers of increased risk for ICH
among patients requiring carotid interventions.
Several observational studies have revealed that the
incidence of postoperative ICH among patients undergo-
ing CEA is in the range of 0.2% to 0.7%.1-4 In contrast, the
reported incidence of ICH after CAS has not been well
established. Although large series of patients undergoing
CAS report similarly low rates between 0.4% and 0.7%,
smaller series with fewer than 100 cases reveal ICH rates as
high as 5%.4,6,9,10,12,19,20 Our results revealed significant
differences in ICH rates after CAS and CEA, with signifi-
cantly higher risk of acute ICH after CAS. Of note, our data
is restricted to ICH that occurred during the same hospi-
talization after carotid interventions. Because most epi-
sodes of ICH after CEA are related to HPS and occur
several days after the intervention, the true incidence of
this complication after carotid interventions is not re-
ported in this study. Unfortunately, follow-up informa-
tion cannot be obtained because the NIS dataset is
thoroughly de-identified and restricted to inpatient data.
ICH after carotid interventions has usually been attrib-
uted to HPS.5 A second type of acute ICH has also been
described.6,12 In contrast to the delayed form associated
with HPS, acute ICH occurs after a short postprocedural
time course and resembles hypertensive ICH. It is usually
fatal. Coutts et al6 were the first to emphasize the distinc-
tion between the early and delayed types of HPS and ICH
be im
lue 
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categories of HPS could be differentiated: two occurred
within a few hours after the carotid intervention whereas
the “classic” delayed type of presentation occurred days
after the procedure. The two early types include acute focal
edema and acute ICH. The respective outcomes were
significantly different: acute edema was associated with
favorable outcome whereas acute ICH was typically fatal.
Buhk et al12 have further suggested that acute ICH resem-
bles hypertensive ICH and appears to be more frequent
after CAS. Large observational studies have further dem-
onstrated that the onset of HPS peaks on postoperative day
6 in patients undergoing CEA and within 12 hours in those
undergoing CAS.4 Our results are consistent with these
observations and suggest that acute ICH is significantly
more frequent after CAS compared to CEA.
The difference in timing of ICH between the two
carotid interventions cannot be easily explained. Distal
cerebral embolization and subsequent ICH in areas of
infarction may account for the increased risk of acute ICH
after CAS. Several observational studies have in fact re-
vealed that release of atherosclerotic fragments from ca-
rotid plaque occurs during virtually all CAS procedures and
that a high proportion of stented carotid lesions continue
to release embolic material after the procedure.20-22 These
embolic episodes occur more frequently after CAS than
after CEA.23 Superimposed cerebral reperfusion can lead to
hemorrhagic transformation of the areas of infarction.5
However, because ICH is not necessarily associated with
impaired autoregulation of cerebral blood flow under these
circumstances, it cannot be attributed to HPS.
CAS frequently induce bradycardia and hypotension
secondary to catheter instrumentation of the carotid
bulb.24-26 Balloon inflation and stent placement are re-
sponsible for the direct stimulation of the carotid barore-
Table II. Independent predictors of intracranial hemorrha
Coefficient
Intracranial hemorrhage
CAS (vs CEA) 1.754
Age 0.055






CAS (vs CEA) 0.398
Age 0.013




Symptomatic carotid stenosis 0.629
Intracranial hemorrhage 1.388
CEA, carotid endarterectomy; CAS, carotid artery stenting.
*Variables with a P value .25 in the univariate analysis and those known to
logistic regression models and selected by forward stepwise selection if P vaceptors, which in turn may result in neuronal responsesmanifested as hemodynamic depression.27 Bradycardia is
primarily related to increased parasympathetic discharges,
whereas hypotension is caused by inhibition of the sympa-
thetic tone. Hemodynamic depression has been associated
with significant morbidity and mortality if not resolved
expeditiously.28-30 Cerebral ischemia secondary to hemo-
dynamic depression may occur more frequently during
CAS compared with CEA resulting in severe endothelial
injury secondary to hyperperfusion and reperfusion,
thereby increasing the risk of ICH in the early postoperative
period.5 A direct association between hemodynamic de-
pression and ICH, however, has not been demonstrated.
Although acute hemorrhagic transformation of recent
cerebral infarctions may account for the higher incidence of
early ICH after CAS compared with CEA, pre-existing
ischemic stroke has not consistently been associated with
either HPS or ICH after carotid interventions. In our
study, patients with symptomatic carotid stenosis and those
presenting with ischemic stroke did not have an increased
risk of ICH. A serious limitation of this study, however, is
defining symptomatic status using ICD-9-CM codes. Sig-
nificant undercoding and under-reporting that frequently
occurs with administrative datasets may result in underes-
timation of the true frequency of symptomatic carotid
stenosis in this study.
Subarachnoid hemorrhage has been reported to occur
more frequently after CAS compared to CEA.4,6,9,10 In the
NIS dataset, however, no instances of subarachnoid hem-
orrhage were reported after neither CAS nor CEA, proba-
bly because of undercoding. Although undercoding is an
inherent limitation of most administrative datasets, it prob-
ably occurs at a similar frequency after both CAS and CEA.
Future studies are needed to define the true incidence and
clinical significance of subarachnoid hemorrhage after ca-
nd death after carotid interventions*
s Ratio† 95% Confidence Interval P value
5.90 3.1-11.1  .001
1.02 1.01-1.02 .003
1.35 1.1-1.7 .005
4.70 5.8-37.2  .001
4.49 1.8-11.4 .002
1.99 1.1-3.9 .044
5.71 2.4-13.5  .001
1.49 1.2-18  .001
1.01 1.01-1.02 .001
1.37 1.3-1.4  .001
4.07 3.5-4.7  .001
1.28 1.1-1.5 .001
1.92 1.5-2.4  .001
1.88 1.6-2.2  .001
4.01 1.5-10.9 .007
portant and possible confounding factors were entered into the multivariate
.05 (P  .001 for models).ge a
Odd
1rotid interventions.
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sion, renal failure, female gender, and nonelective admis-
sion, in addition to CAS, were identified as independent
predictors of ICH after carotid interventions. Previous
studies have demonstrated similar risk factors for ICH after
both CEA and CAS.4,9 Of note, an association between
hypertension and an increased risk of HPS and ICH after
carotid interventions have consistently been reported. In
our series, hypertension was associated with a twofold
increased risk of acute ICH after carotid interventions.
Aggressive treatment of hypertension in patients at high-
risk for HPS has been shown to effectively reduce the risk of
ICH after CEA.8 More recently, a similar approach in
patients undergoing CAS has resulted in a lower inci-
dence of HPS and ICH.31 These studies underscore the
importance of treating hypertension in patients under-
going carotid interventions to reduce the risk of postpro-
cedural ICH.
In the present study, the mortality rates were signifi-
cantly higher in patients with ICH after carotid interven-
tions compared with those that did not develop this com-
plication. These results are consistent with previous reports
of poor prognoses for ICH after both CAS and CEA.4,19 In
our series, 26% of patients that developed acute ICH and
underwent CAS died during the same hospitalization,
whereas no deaths occurred among patients that developed
ICH after CEA. Thus, ICH after CAS was associated with
a 34-fold increased risk of in-hospital mortality (OR, 33.9;
95% CI, 12-95; P  .001). We acknowledge that the
absence of death among patients that developed ICH after
CEA may be explained by undercoding or by late occur-
rence of ICH and HPS after CEA. As noted above, the
incidence of delayed ICH is not known as only in-hospital
major adverse events are available within the NIS dataset.
Although the present study includes the nationwide
experience with carotid interventions performed in the
United States in 2005, several important limitations should
be acknowledged. First, miscoded and missing data can
occur in large administrative datasets, such as the NIS.
However, potential undercoding and misclassifications
would have occurred without bias toward either of the two
procedure groups. Second, the NIS dataset only includes
in-hospital ICH, stroke, and death rates, which may erro-
neously be considered too low compared with the usually
reported 30-day rates of major adverse events after carotid
interventions. Third, the role of dual antiplatelet therapy on
the incidence of ICH after CAS could not be assessed in our
study as this information was not available. Patients under-
going CAS, however, usually receive dual antiplatelet ther-
apy as opposed to those undergoing CEA. The possible
role of dual antiplatelet therapy in patients undergoing
CAS as a possible etiology factor for the higher incidence of
ICH after CAS compared with CEA is further supported by
previous studies revealing a higher incidence of ICH with
the use of dual antiplatelet therapy as opposed to aspirin
alone in high-risk neurologic patients.32 Again, it is unfor-
tunate that the type of antiplatelet therapy in patients
undergoing carotid interventions is not recorded in theNIS dataset. Finally, anatomic, lesion, procedural, and
other patient and treatment characteristics, such as with-
holding antihypertensive medications prior to CAS, that
could be explored as possible predictors of ICH are not
available in the NIS dataset. Given these limitations, case-
and-effect relationships based on the results of this study
cannot be drawn. Future studies assessing their effects on
the incidence and outcomes of ICH after carotid interven-
tions are needed.
In conclusion, patients undergoing CAS in the United
States have not only significantly increased postoperative
stroke and death rates compared with those undergoing
CEA, but also a sixfold increased risk of ICH. CEA may in
fact be safer than CAS in patients with increased risk of
ICH. Further studies are necessary, however, to identify
patient and lesion characteristics that increase the risk of
ICH among patients requiring carotid interventions. Al-
though ICH after CAS is extremely rare, its devastating
nature and high mortality warrant further investigation to
define specific risk factors and to determine prevention and
treatment strategies.
AUTHOR CONTRIBUTIONS
Conception and design: WS, TP, UM, AV
Analysis and interpretation: KB, SR, EG, WS
Data collection: KB, SR, TP, AV
Writing the article: KB, SR, AV, TP, WS
Critical revision of the article: WS, AV, UM
Final approval of the article: WS, AV, TP, UM
Statistical analysis: KB, SR, EG
Obtained funding: Not applicable
Overall responsibility: WS, KB, TP
REFERENCES
1. Hafner DH, Smith RB III, King OW, Perdue GD, Stewart MT,
Rosenthal D, et al. Massive intracerebral hemorrhage following carotid
endarterectomy. Arch Surg 1987;122:305-7.
2. Pomposelli FB, Lamparello PJ, Riles TS, Craighead CC, Giangola G,
Imparato AM. Intracranial hemorrhage after carotid endarterectomy.
J Vasc Surg 1988;7:248-55.
3. Piepgras DG, Morgan MK, Sundt TM Jr, Yanagihara T, Mussman LM.
Intracerebral hemorrhage after carotid endarterectomy. J Neurosurg
1988;68:532-6.
4. Ogasawara K, Sakai N, Kuroiwa T, Hosoda K, Iihara K, Toyoda K, et al.
Intracranial hemorrhage associated with cerebral hyperperfusion syn-
drome following carotid endarterectomy and carotid artery stenting:
retrospective review of 4494 patients. J Neurosurg 2007;107:1130-6.
5. van Mook WN, Rennenberg RJ, Schurink GW, van Oostenbrugge RJ,
Mess WH, Hofman PA, et al. Cerebral hyperperfusion syndrome.
Lancet Neurol 2005;4:877-88.
6. Coutts SB, Hill MD, Hu WY. Hyperperfusion syndrome: toward a
stricter definition. Neurosurgery 2003;53:1053-8.
7. Ascher E, Markevich N, Schutzer RW, Kallakuri S, Jacob T, Hingorani
AP. Cerebral hyperperfusion syndrome after carotid endarterectomy:
predictive factors and hemodynamic changes. J Vasc Surg 2003;37:
769-77.
8. Ouriel K, Shortell CK, Illig KA, Greenberg RK, Green RM. Intracere-
bral hemorrhage after carotid endarterectomy: incidence, contribution
to neurologic morbidity, and predictive factors. J Vasc Surg 1999;29:
82-7.
9. Abou-Chebl A, Yadav JS, Reginelli JP, Bajzer C, Bhatt D, Krieger DW.
Intracranial hemorrhage and hyperperfusion syndrome following ca-
JOURNAL OF VASCULAR SURGERY
March 2009628 Timaran et alrotid artery stenting: risk factors, prevention, and treatment. J Am Coll
Cardiol 2004;43:1596-601.
10. Morrish W, Grahovac S, Douen A, Cheung G, Hu W, Farb R, et al.
Intracranial hemorrhage after stenting and angioplasty of extracranial
carotid stenosis. AJNR Am J Neuroradiol 2000;21:1911-6.
11. Meyers PM, Higashida RT, Phatouros CC, Malek AM, Lempert TE,
Dowd CF, et al. Cerebral hyperperfusion syndrome after percutaneous
transluminal stenting of the craniocervical arteries. Neurosurgery 2000;
47:335-43.
12. Buhk JH, Cepek L, Knauth M. Hyperacute intracerebral hemorrhage
complicating carotid stenting should be distinguished from hyperper-
fusion syndrome. AJNR Am J Neuroradiol 2006;27:1508-13.
13. Ohki T, Timaran CH, Yadav JS. Technique of carotid angioplasty and
stenting. In: Moore WS, editor. Vascular and Endovascular Surgery. A
Comprehensive Review. 7th ed. Philadelphia: Saunders Elsevier; 2006.
p.355-82.
14. Overview of the Nationwide Inpatient Sample (NIS) of the Healthcare
Cost and Utilization Project (HCUP). http://www.hcup-us.ahrq.
gov/nisoverview.jsp. Accessed January 4, 2008.
15. Healthcare Cost and Utilization Project (HCUP) Quality Control
Procedures. http://www.hcup-us.ahrq.gov/db/quality.jsp. Accessed
January 2, 2008.
16. Healthcare Cost and Utilization Project (HCUP) Clinical Classifica-
tions Software (CCS). http://www.hcup-us.ahrq.gov/toolssoftware/
ccs/ccs.jsp. Accessed January 4, 2008.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index
for use with ICD-9-CM administrative databases. J Clin Epidemiol
1992;45:613-9.
18. Karp HR, Flanders WD, Shipp CC, Taylor B, Martin D. Carotid
endarterectomy among Medicare beneficiaries : a statewide evaluation
of appropriateness and outcome. Stroke 1998;29:46-52.
19. Kang HS, Han MH, Kwon OK, Kwon BJ, Kim SH, Oh CW. Intracra-
nial hemorrhage after carotid angioplasty: a pooled analysis. J Endovasc
Ther 2007;14:77-85.
20. Fairman R, Gray WA, Scicli AP, Wilburn O, Verta P, Atkinson R, et al.
The CAPTURE registry: analysis of strokes resulting from carotid artery
stenting in the post approval setting: timing, location, severity, and
type. Ann Surg 2007;246:551-6.
21. Rapp JH, Wakil L, Sawhney R, Pan XM, Yenari MA, Glastonbury C,
et al. Subclinical embolization after carotid artery stenting: new lesions
on diffusion-weighted magnetic resonance imaging occur postproce-
dure. J Vasc Surg 2007;45:867-74.
study is that intracranial hemorrhage occurs more frequently after22. Bosiers M, Deloose K, Verbist J, Peeters P. Review of stents for the
carotid artery. J Cardiovasc Surg (Torino) 2006;47:107-13.
23. Roh HG, Byun HS, Ryoo JW, Na DG, Moon WJ, Lee BB, et al.
Prospective analysis of cerebral infarction after carotid endarterectomy
and carotid artery stent placement by using diffusion-weighted imaging.
AJNR Am J Neuroradiol 2005;26:376-84.
24. Bagshaw RJ, Barrer SJ. Effects of angioplasty upon carotid sinus me-
chanical properties and blood pressure control in the dog. Neurosur-
gery 1987;21:324-30.
25. Mendelsohn FO, Weissman NJ, Lederman RJ, Crowley JJ, Gray JL,
Phillips HR, et al. Acute hemodynamic changes during carotid artery
stenting. Am J Cardiol 1998;82:1077-81.
26. Qureshi AI, Luft AR, SharmaM, Janardhan V, Lopes DK, Khan J, et al.
Frequency and determinants of postprocedural hemodynamic instabil-
ity after carotid angioplasty and stenting. Stroke 1999;30:2086-93.
27. Harrop JS, Sharan AD, Benitez RP, Armonda R, Thomas J, Rosenwas-
ser RH. Prevention of carotid angioplasty-induced bradycardia and
hypotension with temporary venous pacemakers. Neurosurgery 2001;
49:814-20.
28. Dangas G, Laird JR Jr, Satler LF, Mehran R,Mintz GS, Larrain G, et al.
Postprocedural hypotension after carotid artery stent placement: pre-
dictors and short- and long-term clinical outcomes. Radiology 2000;
215:677-83.
29. Howell M, Krajcer Z, Dougherty K, Strickman N, Skolkin M, Toombs
B, et al. Correlation of periprocedural systolic blood pressure changes
with neurological events in high-risk carotid stent patients. J Endovasc
Ther 2002;9:810-6.
30. Gupta R, Abou-Chebl A, Bajzer CT, Schumacher HC, Yadav JS. Rate,
predictors, and consequences of hemodynamic depression after carotid
artery stenting. J Am Coll Cardiol 2006;47:1538-43.
31. Abou-Chebl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of
hypertension decreases the risk of hyperperfusion and intracerebral
hemorrhage following carotid artery stenting. Catheter Cardiovasc
Interv 2007;69:690-6.
32. Diener PH-C, Bogousslavsky PJ, Brass PL, Cimminiello PC, Csiba PL,
Kaste PM, et al. Aspirin and clopidogrel compared with clopidogrel
alone after recent ischaemic stroke or transient ischaemic attack in
high-risk patients (MATCH): randomised, double-blind, placebo-
controlled trial. Lancet 2004;364:331-7.Submitted Jul 3, 2008; accepted Sep 10, 2008.DISCUSSION
Dr Thomas Riles (New York, NY). Generally we think of
postoperative intracranial hemorrhage being due to individuals
who have had a recent stroke and who also have very high-grade
stenosis. The perioperative hemorrhagic stroke results from reper-
fusing a bland stroke by opening up the artery and increasing the
pressure into that area. You didn’t really mention those as risk
factors here. I wanted to know what you thought about that or if
you think that this is an entirely different mechanism of stroke,
maybe related to the antiplatelet agents.
Dr Timaran. The NIS data includes diagnostic codes for
preoperative stroke. So we can define the number of patients that
had strokes before the interventions. We did include that variable
in our analysis, and we did not find any significant differences in the
frequency of intracranial hemorrhage in those patients that had
preoperative stroke vs those that did not have stroke. Obviously, it
is important to know the timing or the interval between the stroke
and the intervention, but unfortunately those data are not avail-
able.
Obviously, dual antiplatelet therapy may be an important
mechanism not only for the severity but also for the associated
mortality of this complication. But we cannot prove that this is the
mainmechanism as this data are not available either. I think that we
need further studies to define that. All we can conclude from ourcarotid stenting and that we have to take that into consideration in
specific patients.
Dr Isabelle Van Herzeele (Gent, Belgium). I just had two
queries. First of all, I was wondering if you could comment on the
indication for carotid artery stenting. You mentioned that only
3.6% of your patients had a symptomatic carotid artery stenosis.
However, currently there is no evidence for carotid artery stenting
in asymptomatic patients and that’s why trials are underway,
should we not await the results of these trials and include asymp-
tomatic patients in these trials prior to widespread use of CAS for
asymptomatic lesions?
Secondly, you also acknowledge that the patients who did
receive carotid artery stenting were high-risk patients. As we know
from the Asymptomatic Carotid Surgery Trial (ACST), patients
with asymptomatic carotid lesions, should only be offered inter-
ventions if they have a life expectancy of at least 5 years. I wonder
if you could expand on these comments.
Dr Timaran. I do agree. The way we define symptomatic
patients used in this cohort is probably not perfect. That is why we
are underestimating the number of symptomatic patients included.
But there is no question that in this country most carotid interven-
tions are performed for asymptomatic patients. And I do believe
most asymptomatic patients, at least in this cohort, were consid-
ered high risk. Again, we tried to adjust for risk factors. We even
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kind of datasets, but that’s all we have. And probably, yes, we have
not adjusted for all the risk factors we should.
Dr Ali AbuRahma (Charleston, WVa). As Dr Riles sug-
gested, not only are there other factors associated with intracranial
hemorrhage, but also the carotid artery stent protocol varies from
one trial to another. All of them use a loading dose of Plavix,
followed by Plavix and aspirin daily, but a few trials also added
heparin for the first 24 hours. Have you noticed any difference in
outcome with the use of heparin?
Dr Timaran. Unfortunately, we don’t have data about anti-
coagulation or about specific types of antiplatelet therapy. But
obviously those are important considerations. They need to be
studied further.
Dr Christos Liapis (Athens, Greece). Thank you for bringing
to our attention a very important matter, which is becoming even
more important with the common practice of sending the patients
home only 24 hours after carotid stenting. I have a couple of
questions.
1. Do you have any data regarding the timing of the occurrence of
the hemorrhage?
2. Any information regarding staging between bilateral carotid
procedures and intracerebral hemorrhage?
Dr Timaran. No, we don’t have any data about when these
episodes happened. Again, all these events of intracranial hemor-
rhage occurred during the same hospitalization. That would be
one of the limitations of this study in which we are missing those
patients that underwent CEA and developed intracranial hemor-
rhage, because most of those patients actually may develop the
complication after their discharge. Again, unfortunately, we don’t
have that type of information from this dataset.
Dr Christos Liapis. How about the staging? Because, as we
know, if you operate on one side, then by destroying the barore-
ceptors you may have an uncontrolled hypertension while operat-
ing on the other side.
Dr Timaran. We don’t have any answer about that either.
Dr Jonathan Golledge (Queensland, Australia). It seems,
watching this morning’s session, that carotid stenting is taking a bit
of a battering. And being a fair sort of person, I thought I should
point out that I recently saw a paper in Radiology that suggested
that after carotid stenting there was less depression in the patients
than beforehand. I promptly sent the paper to our local psychiatrist
and suggested he was no longer needed. So my question was haveyou noticed that patients were any happier following carotid
stenting?
Dr Timaran. No, unfortunately, we don’t have that type of
information.
But I have to say, however, that at our institution we have
performed 270 carotid stenting procedures and the case I showed
you during my presentation is the only stroke we have had in that
series. We have not had major or minor ischemic strokes, only this
one. And believe me that was very devastating. This patient was my
fifth carotid stenting patient. And that’s why I’ve always been
concerned about this type of complication because this is some-
thing you cannot avoid, at least from the technical standpoint.
There may be patient selection issues that may actually allow you to
prevent it. As far as depression after carotid stenting, I don’t have
additional data to contribute.
Dr Golledge. So it may be that the technician is more de-
pressed but the patient is happier.
Dr John Ricotta (Stony Brook, NY). I’m a little concerned
about your ascribing this to dual antiplatelet therapy. I use dual
antiplatelet therapy routinely on my endarterectomy patients and I
think a lot of people do that.
CAS is a procedure where a wire is placed in the distal internal
carotid artery. At the end of that procedure, if you do diffusion
MRI, there are a lot of small defects intracranially. You need to
think about whether we’re setting up with the stenting procedure
a better bed for intracranial hemorrhage when you do get reperfu-
sion. I think this is a reperfusion injury that then becomes hemor-
rhagic.
So I would just ask for your comments on whether you really
think it’s dual antiplatelet therapy or whether some other things
that are specific to the stenting procedure may be the cause.
Dr Timaran. The fact that mortality of intracranial hemor-
rhage after carotid stenting appears to be higher and also the fact
that intracranial hemorrhage appears to occur very early after the
procedure, may actually indicate that there are several factors going
on of which dual antiplatelet therapy may be one of them. Small
ischemic areas in the brain, because of the procedure itself, may
also account for that. Or other variables that we don’t know, such
as the presence of bilateral severe carotid stenosis, contralateral
occlusion, hypertension, etc, or all of them together I think ac-
count for a higher incidence of intracranial hemorrhage and a
higher mortality.
